Abstract 4344
Background
CV301 is an MVA-based vaccine encoding human transgenes MUC1, CEA and TRICOM. A phase I dose-escalation trial (Gatti-Mays E, et al. CCR 2019) concluded that CV301 is safe in advanced cancer patients and generated specific T cell responses against the encoded antigens. Preclinical data supports the rational for combining CV301 with PD-1 inhibitors. The primary objective of this trial was to evaluate safety and tolerability of this combination.
Methods
Patients with advanced non-squamous-NSCLC without actionable alterations in EGFR, ALK and ROS1 were eligible. Two priming doses of MVA-BN-CV301 (MVA) were administered in 4 separate subcutaneous (SC) injections of 4x10^8 IU, 4 weeks apart, followed by boosting doses of Fowlpox-CV301 (FPV) given as a single injection of 1x10^9 IU SC q2w for weeks 9-15, q4w for weeks 19-51 and q13w up to 17 doses for Cohort 1 (C1), q3w for weeks 7-22, q6w for weeks 28-52 and q12w up to 15 doses for Cohort 2 (C2). C1 included patients pre-treated with platinum-containing chemotherapy, who were considered eligible for nivolumab (N; 240 mg IV q2w). C2 included patients receiving frontline treatment with pembrolizumab (P; 200 mg IV q3w) after a minimum of 11 weeks of SD per RECIST.
Results
Between Oct-2017 and Sep-2018, 12 pts were recruited, 4 in C1 and 8 in C2. Median age was 64, and 9 pts were F. Majority of patients were former-smokers (9, 1 current, 2 never). As of Mar-2019 data cut-off, mean treatment duration was 272 days in C1 and 193 days in C2, with 7 pts continuing and 5 discontinuing treatment. Both doses of MVA were administered to 3/4 pts in C1 and 7/8 pts in C2. Median FPV doses/pt: C1=12 and C2=6. CV301 injection-site reactions and flu-like symptoms were observed in all C1 and 7/8 C2 pts. CTCAE ≥ grade 3 AEs were observed in 3/4 C1 and 3/8 C2 pts with 1 fatal TEAE. IRAEs included 1 autoimmune hepatitis, and 1 pneumonitis fulfilling criteria of DLT. As of data-cut, we observed 1 CR (C1), 10 SD, and 1 discontinuation prior to first scheduled RECIST assessment.
Conclusions
The treatment of NSCLC with CV301 + N or P is feasible and tolerated, with no observed increase in the frequency or severity of expected AEs or IRAEs for each component of the combination.
Clinical trial identification
NCT02840994.
Editorial acknowledgement
Legal entity responsible for the study
Bavarian Nordic Inc.
Funding
Bavarian Nordic Inc.
Disclosure
C. Heery: Honoraria (self), Leadership role: Bavarian Nordic. C. Pico-Navarro: Honoraria (self): Bavarian Nordic. M. Piechatzek: Full / Part-time employment: Bavarian Nordic. E. Wagner: Full / Part-time employment: Bavarian Nordic. E. Menius: Full / Part-time employment: Bavarian Nordic. All other authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract